CDC-RFA-PS-24-00470101SUPP24: High-Impact HIV Prevention and Surveillance Programs for Health Departments: Accelerating Pre-Exposure Prophylaxis (PrEP) Uptake for Ending the HIV Epidemic in the United States
Closed
This grant is closed. A newer notice from the same program is forecast: Demonstration Projects for Whole-Person Health Models for Women Living with HIV in the South (CDC-RFA-PS-27-0061). Status: Expected deadline March 15, 2027. It is in our archive of Centers for Disease Control - NCHHSTP notices from 2024.
Centers for Disease Control - NCHHSTP offered grants to state and local governments. It expected to make about 4 awards worth $1.8 million in total. Applications closed on August 31, 2024.
From the official notice on Grants.gov, last changed August 1, 2024. Checked November 7, 2026.
- Total funding$1.8 million
- Expected awards4
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | August 1, 2024 |
|---|---|
| Deadline | August 31, 2024 |
| Archived by Grants.gov | September 30, 2024 |
Who can apply
This opportunity was open to state and local governments.
- State governments
- County governments
- City or township governments
- Special district governments
Due to statutory authority, this supplemental funding opportunity is offered to the 32 state, local and territorial health departments currently receiving Ending the HIV Epidemic in the U.S. (EHE) funding under notice of funding opportunity (NOFO) PS24-0047: High-Impact HIV Prevention and Surveillance Programs for Health Departments.
Is this a realistic fit?
- Most of the program's money (97% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
CDC announces the availability of approximately $7 million in competitive supplemental funding for the 32 health department jurisdictions currently receiving Ending the HIV Epidemic in the US (EHE) initiative funding resources under notice of funding opportunity (NOFO) PS24-0047: High-Impact HIV Prevention and Surveillance Programs for Health Departments. Fully aligned with PS24-0047, the supplemental NOFO prioritizes acceleration of progress toward achieving the national HIV prevention goal of 50% pre-exposure prophylaxis (PrEP) coverage by the end of 2025. Jurisdictions with greater need for PrEP and lower uptake among priority populations disproportionately affected by HIV and low PrEP prescriptions (i.e., Black and Latino gay, bisexual, and other men who have sex with men (MSM), and Black cisgender and transgender women) need these additional resources and flexibility to accelerate PrEP uptake through patient navigation/case management services and improve access to and utilization of existing PrEP services not covered by other financial resources. Recipients will implement enhanced and expanded programmatic activities to increase access to and uptake of PrEP for priority populations and to help further eliminate structural and social barriers that prevent equitable access to PrEP within EHE jurisdictions. Additionally, these enhanced and expanded PrEP programs will incorporate elements to increase HIV non-occupational post-exposure prophylaxis (PEP) and doxycycline post-exposure prophylaxis (doxy PEP) awareness and access, including activities with clinicians, non-clinical community-based organizations (CBOs), and persons at risk for HIV acquisition. The supplemental NOFO's period of performance is September 30, 2024 - May 31, 2025 (8 months). Recipients may request to continue implementation of supplemental programmatic activities during PS24-0047 Budget Year 2 (June 1, 2025 - May 31, 2026). Recipients will implement concurrently all required programmatic activities as described in both PS24-0047 and the forthcoming supplemental NOFO.
Who has won HIV Prevention and Surveillance Activities-Health Department Based grants before
From fiscal 2021 to 2025, HIV Prevention and Surveillance Activities-Health Department Based (93.940) awarded $1.8 billion across 463 grant awards, an average of $3.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Florida Department of Health | Florida | 9 | $183 million |
| City of New York | New York | 8 | $147 million |
| California Department of Public Health | California | 7 | $119 million |
| Department of State Health Services | Texas | 7 | $92.7 million |
| County of Los Angeles | California | 9 | $88.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-PS-27-0061, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-PS-24-00470101SUPP24 still open?
No. It closed on August 31, 2024. A newer notice is forecast: CDC-RFA-PS-27-0061, expected deadline March 15, 2027.
Who can apply for High-Impact HIV Prevention and Surveillance Programs for Health Departments: Accelerating Pre-Exposure Prophylaxis (PrEP) Uptake for Ending the HIV Epidemic in the United States?
Centers for Disease Control - NCHHSTP accepted applications from state and local governments. The notice adds further conditions, so read its eligibility section.
What is the deadline for High-Impact HIV Prevention and Surveillance Programs for Health Departments: Accelerating Pre-Exposure Prophylaxis (PrEP) Uptake for Ending the HIV Epidemic in the United States?
Closed August 31, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $1.8 million in total across about 4 awards.
Who has won HIV Prevention and Surveillance Activities-Health Department Based grants before?
The largest recipients over five fiscal years were Florida Department of Health, City of New York, California Department of Public Health. The program made 463 awards worth $1.8 billion in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)